| External factors: | Ribociclib |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Adrenocortical carcinomas |
| Experiment: | SA-β-gal activity assay//Flow cytometry |
| Description: | In SW-13 cells, 1 and 5 μM of both inhibitors induced cell cycle arrest, with a smaller proportion of cells in the S phase and an increased proportion of cells in the G1 and G2 phases, when compared with mock-treated cells. The cycle of NCI-H295R cells was also affected by drug treatments. 10 μM Palbociclib increased the proportion of cells in G2 phase, whereas 10 μM ribociclib increased the proportion of cells in S phase.In SW-13 cells treated with palbociclib or ribociclib, we observed a significant increase in the percentage of cells harboring β-galacto-sidase activity, an indicator of senescence. |
| Target gene: | PHOSPHO-RB |
| R-EF-Target gene: | Downregulation |
| Official symbol(s): | PHOSPHO-RB |
| Target gene experiment: | Western blot |
| Target gene description: | In SW-13 cells, the amount of both CDK4 and CDK6 proteins increased after treatment with palbociclib or ribociclib. Such treatments also significantly lowered the amounts of both Phospho-Rb and pRB. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: